A mixture Covid/flu shot may have a number of benefits.
dpa/image alliance through Getty Pictures
On Wednesday, Maryland-based vaccine producer Novavax launched preliminary outcomes from an early scientific part research of its mixture Covid/flu vaccine. The outcomes discovered that the mix vaccine produced immune responses in sufferers that have been comparable with these of its stand-alone flu and Covid vaccines. The corporate additionally discovered the vaccine formulation to be secure, with largely delicate uncomfortable side effects.
“We’re inspired by these information and the potential path ahead for a mix Covid-19-influenza vaccine in addition to stand-alone vaccines for influenza and Covid-19,” Gregory Glenn, Novavax’s president of R&D, stated in a press release.
Novavax’s vaccine differs from the mRNA vaccines developed by Pfizer, BioNTech and Moderna. Its vaccines use nanoparticles that mimic proteins from the coronavirus or influenza virus (or each, within the case of the mix vaccine). The nanoparticles are injected into sufferers together with an adjuvant, which is a chemical that helps stimulate the immune system, which causes the sufferers to develop antibodies in opposition to Covid and flu.
The corporate’s flu vaccine is at present in part 3 trials. At a media briefing on Wednesday morning, Novavax’s chief medical officer Filip Dubovsky stated information from these trials thus far present larger antibody responses for sufferers with Novavax’s vaccine in opposition to a number of strains of flu in comparison with sufferers who acquired an accepted flu vaccine. Full efficacy information was not offered, however Dubovsky highlighted equally excessive antibody responses in opposition to H3N2 flu strains, in opposition to which present vaccines have low efficacy.
Novavax’s Covid vaccine has been licensed to be used in over 40 international locations around the globe, together with the EU and most recently, Japan. The corporate utilized for emergency authorization with the FDA in January. Though the inventory has been trending downward as Covid restrictions proceed to carry in most locations around the globe, Jefferies analysts Roger Tune and Xiangyu Ma wrote in a report Tuesday that issues for the corporate’s long-term prospects are “overstated,” as they see Covid turning into “an endemic illness requiring efficient/tolerated common vaccination.”
The subsequent step for the mix Covid/flu vaccine will probably be a part 2 scientific trial, which Dubovsky says ought to start by the top of this 12 months. That trial will probably be aimed towards optimizing the proper dose for the Covid and flu antigens, in addition to the proper dose for the adjuvant. Following a profitable part 2, a part 3 trial could be timed for a flu season, hopefully in 2023, although Dubovsky admits this may increasingly depend upon what the present Covid state of affairs appears like, as Covid mitigation measures have slowed down the circulation of influenza for the previous two years.
For Dubovsky, the important thing benefit of the mix vaccine is that it requires much less materials than two separate pictures would. So if the trials pan out and the mix vaccine goes in the marketplace, he says, that “permits us to fabricate many extra doses so we are able to attain extra lives.”
Full protection and reside updates on the Coronavirus
